Allergic	allergic	O	DISEASE	OTHERS	I
reaction	reaction	O	DISEASE	OTHERS	I
to	to	O	O	O	O
5-fluorouracil	5-fluorouracil	CHEMICALS	O	OTHERS	I
infusion	infusion	O	O	O	O
.	.	O	O	O	O

An	an	O	O	O	O
allergic	allergic	O	DISEASE	OTHERS	I
reaction	reaction	O	DISEASE	OTHERS	I
consisting	consisting	O	O	O	O
of	of	O	O	O	O
angioneurotic	angioneurotic	O	O	OTHERS	I
edema	edema	O	DISEASE	OTHERS	I
secondary	secondary	O	O	O	O
to	to	O	O	O	O
continuous	continuous	O	O	O	O
infusion	infusion	O	O	O	O
5-fluorouracil	5-fluorouracil	CHEMICALS	O	OTHERS	I
occurred	occurred	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
patient	patient	O	O	O	O
with	with	O	O	O	O
recurrent	recurrent	O	O	O	O
carcinoma	carcinoma	O	DISEASE	OTHERS	I
of	of	O	O	OTHERS	I
the	the	O	O	OTHERS	I
oral	oral	O	O	OTHERS	I
cavity	cavity	O	O	OTHERS	I
,	,	O	O	O	O
cirrhosis	cirrhosis	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
cisplatin-induced	cisplatin-induced	O	O	O	O
impaired	impaired	O	O	OTHERS	I
renal	renal	O	O	OTHERS	I
function	function	O	O	OTHERS	I
.	.	O	O	O	O

This	this	O	O	O	O
reaction	reaction	O	O	O	O
occurred	occurred	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
sixth	sixth	O	O	O	O
and	and	O	O	O	O
seventh	seventh	O	O	O	O
courses	courses	O	O	O	O
of	of	O	O	O	O
infusional	infusional	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
.	.	O	O	O	O

Oral	oral	O	O	O	O
diphenhydramine	diphenhydramine	O	O	OTHERS	I
and	and	O	O	O	O
prednisone	prednisone	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
ineffective	ineffective	O	O	O	O
in	in	O	O	O	O
preventing	preventing	O	O	O	O
the	the	O	O	O	O
recurrence	recurrence	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
allergic	allergic	O	DISEASE	OTHERS	I
reaction	reaction	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Discontinuance	discontinuance	O	O	O	O
of	of	O	O	O	O
effective	effective	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
patient	patient	O	O	O	O
during	during	O	O	O	O
partial	partial	O	O	O	O
remission	remission	O	O	O	O
resulted	resulted	O	O	O	O
in	in	O	O	O	O
fatal	fatal	O	O	O	O
disease	disease	O	DISEASE	OTHERS	I
progression	progression	O	DISEASE	OTHERS	I
.	.	O	O	O	O

